Cargando…

Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

INTRODUCTION: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche, Nicolas, Campbell, Jonathan D., Krishnan, Jerry A., Brusselle, Guy, Chisholm, Alison, Bjermer, Leif, Thomas, Mike, van Ganse, Eric, van den Berge, Maarten, Christoff, George, Quint, Jennifer, Papadopoulos, Nikolaos G., Price, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436229/
https://www.ncbi.nlm.nih.gov/pubmed/30962875
http://dx.doi.org/10.1186/s13601-019-0255-x
_version_ 1783406774060056576
author Roche, Nicolas
Campbell, Jonathan D.
Krishnan, Jerry A.
Brusselle, Guy
Chisholm, Alison
Bjermer, Leif
Thomas, Mike
van Ganse, Eric
van den Berge, Maarten
Christoff, George
Quint, Jennifer
Papadopoulos, Nikolaos G.
Price, David
author_facet Roche, Nicolas
Campbell, Jonathan D.
Krishnan, Jerry A.
Brusselle, Guy
Chisholm, Alison
Bjermer, Leif
Thomas, Mike
van Ganse, Eric
van den Berge, Maarten
Christoff, George
Quint, Jennifer
Papadopoulos, Nikolaos G.
Price, David
author_sort Roche, Nicolas
collection PubMed
description INTRODUCTION: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could be considered within future guideline development. METHODS: The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, version underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and particle size on asthma treatment effectiveness. RESULTS: Although highlighting a general lack of high-quality real-life effectiveness observational research on these clinically important topics, the analysis provided insights into how identified observational studies might inform asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers. CONCLUSIONS: Using such quality appraisal tools is mandatory to assess whether specific observational real-life effectiveness studies can be used to inform guideline development and/or decision-making in clinical practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13601-019-0255-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6436229
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64362292019-04-08 Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force Roche, Nicolas Campbell, Jonathan D. Krishnan, Jerry A. Brusselle, Guy Chisholm, Alison Bjermer, Leif Thomas, Mike van Ganse, Eric van den Berge, Maarten Christoff, George Quint, Jennifer Papadopoulos, Nikolaos G. Price, David Clin Transl Allergy Research INTRODUCTION: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could be considered within future guideline development. METHODS: The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, version underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and particle size on asthma treatment effectiveness. RESULTS: Although highlighting a general lack of high-quality real-life effectiveness observational research on these clinically important topics, the analysis provided insights into how identified observational studies might inform asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers. CONCLUSIONS: Using such quality appraisal tools is mandatory to assess whether specific observational real-life effectiveness studies can be used to inform guideline development and/or decision-making in clinical practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13601-019-0255-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-03-27 /pmc/articles/PMC6436229/ /pubmed/30962875 http://dx.doi.org/10.1186/s13601-019-0255-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Roche, Nicolas
Campbell, Jonathan D.
Krishnan, Jerry A.
Brusselle, Guy
Chisholm, Alison
Bjermer, Leif
Thomas, Mike
van Ganse, Eric
van den Berge, Maarten
Christoff, George
Quint, Jennifer
Papadopoulos, Nikolaos G.
Price, David
Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
title Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
title_full Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
title_fullStr Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
title_full_unstemmed Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
title_short Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
title_sort quality standards in respiratory real-life effectiveness research: the real life evidence assessment tool (relevant): report from the respiratory effectiveness group—european academy of allergy and clinical immunology task force
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436229/
https://www.ncbi.nlm.nih.gov/pubmed/30962875
http://dx.doi.org/10.1186/s13601-019-0255-x
work_keys_str_mv AT rochenicolas qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT campbelljonathand qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT krishnanjerrya qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT brusselleguy qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT chisholmalison qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT bjermerleif qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT thomasmike qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT vanganseeric qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT vandenbergemaarten qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT christoffgeorge qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT quintjennifer qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT papadopoulosnikolaosg qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce
AT pricedavid qualitystandardsinrespiratoryreallifeeffectivenessresearchthereallifeevidenceassessmenttoolrelevantreportfromtherespiratoryeffectivenessgroupeuropeanacademyofallergyandclinicalimmunologytaskforce